The Nigerian economy has seen the closure of many companies, especially multinational firms, which threw many Nigerians into ...

Nigeria, the giant of Africa, has recently experienced a great downturn in its economy, leading to the exodus of several ...

South African grocery retailer Pick n Pay has decided to leave Nigeria, less than five years after it announced with ...

The Federal Government is advancing its commitment to ensure a self-sustaining healthcare system by collaborating with ...

Minister Pate emphasised that GSK’s investment in localised production represents a crucial milestone in Nigeria’s quest for a robust healthcare system, one that effectively addresses the ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

GSK to pay $2.2 billion to settle 93% of Zantac-related lawsuits. GSK targets £38 billion in sales by 2031, but market estimates fall short at £35.7 billion These cases account for 93% of the ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

The Moderna lawsuits echo similar claims made by GSK when it sued Pfizer and BioNTech for allegedly infringing upon the company’s mRNA patents back in April. At the time, Pfizer voiced ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic ...